Physician profile
Aalia Saeed
NPI 1225220791
$6,422.30
in general payments reported to CMS, 2019-2025
29 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $142 · 2021: $341 · 2022: $274 · 2023: $1,336 · 2024: $2,290 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,101 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,100.74 |
| Education | $108.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,437.12 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $885.17 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $813.75 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $614.65 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $399.07 | 2023-2025 | Dupixent |
| Pfizer INC. | $390.90 | 2019-2025 | |
| Ardelyx, INC. | $301.42 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $208.43 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $150.59 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $133.49 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $132.79 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $121.35 | 2024 | Rebyota |
| Amgen INC. | $120.96 | 2023 | Avsola |
| Phathom Pharmaceuticals, INC. | $104.87 | 2024 | Voquezna |
| Ani Pharmaceuticals, INC. | $104.10 | 2024 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $93.38 | 2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $60.73 | 2021 | |
| Celgene Corporation | $55.85 | 2021-2024 | Zeposia |
| Shionogi INC | $49.30 | 2019-2020 | |
| Genzyme Corporation | $43.36 | 2024-2025 | |
| Mauna Kea Technologies, INC. | $31.69 | 2024 | |
| Organon LLC | $28.82 | 2024-2025 | Hadlima |
| Sandoz INC. | $27.99 | 2025 | Hyrimoz |
| Celltrion USA INC. | $24.17 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $23.14 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $19.23 | 2022 | |
| Axonics, INC. | $16.08 | 2020 | |
| Allergan, INC. | $15.51 | 2019 | |
| Capsovision, INC. | $14.39 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aalia Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.